BioPhase Solutions

Forecasts suggest the biotech industry will surge to over $5 trillion by 2034, fueled by demand for AI, personalized medicine, and climate-resilient tech.

Growth this big doesn't come around often.
Get the full outlook on Investopedia: https://www.investopedia.com/understanding-the-biotech-boom-11736120

Biotech Boom: How Revolutionary Advancements Are Shaping Stock Market Trends The biotech boom, driven by demand for new treatments and sustained by a surge of capital investment, offers new opportunities for investors. But there are risks to be aware of.

The U.S. Orphan Cures Act now extends price-negotiation exemptions to drugs that treat multiple rare conditions, creating a new financial incentive for innovation in one of biotech’s most challenging sectors.

A small policy shift with a big potential impact.

Read on Wall Street Journal: https://www.wsj.com/articles/a-bright-spot-for-biotech-in-trumps-megabill-53111f1d

A Bright Spot for Biotech in Trump’s Megabill Folded into the blockbuster law that passed this month was the Orphan Cures Act, a measure that spares drugs approved for more than one orphan disease from Medicare price negotiation.

Chugai Pharma is working on a game-changing obesity treatment, combining a GLP-1 drug with GYM329, a therapy designed to preserve muscle mass during weight loss. If successful, this could be the new standard of care.

Slim down without the side effects? We’ll take it.
Details via Financial Times: https://www.ft.com/content/4fd1fd94-0b70-48fb-861b-3bad6286ebae?utm_source=chatgpt.com

Biotech behind Eli Lilly obesity pill aims for new standard of care Chugai Pharmaceutical sees potential for combining orforglipron with its drug to tackle muscle wasting

The UK wants to be the world’s biotech leader, but can it deliver?

The British government has invested £650 million into biotech, hoping to make the UK a global life sciences powerhouse by 2035. But without more targeted funding in new medicines, critics say the vision may fall flat.

Ambition is great—execution is better.

Read more on The Times: https://www.thetimes.com/business-money/technology/article/life-sciences-plan-not-enough-without-investment-in-medicines-xd8qcxtmz

Life sciences plan ‘not enough’ without investment in medicines The UK’s life sciences sector plan faces criticism for a lack of research funds and there is tension over negotiations to reform an NHS sales rebate agreement

U.S. pharma tariffs could reshape global supply chains.

Starting this August, the U.S. will begin phasing in pharmaceutical tariffs aimed at onshoring drug manufacturing. While this could mean better supply security, it also has global players scrambling. What does it mean for biotech pricing and production?

Dive into the policy impact: https://www.investors.com/news/technology/pharmaceutical-tariffs-august-2025-drug-stocks/

Pharma Tariffs Expected In August. But The Stocks Just Yawned. President Donald Trump said late Tuesday his administration will begin implementing pharmaceutical tariffs next month.

Lab-grown meat. Plastic-eating enzymes. DNA as the new USB stick. Biotech is quietly leading the charge toward a more sustainable planet—and investors are starting to notice.

Synthetic biology isn't just the future. It’s the solution.

Read more on World Stock Watch: https://worldstockwatch.com/2025/01/16/biotech-boom-5-trends-to-watch-in-2025/

Biotech Boom: 5 Trends to Watch in 2025 - World Stock Watch Discover why 2025 could be a breakout year for biotech stocks, driven by advancements in AI, gene editing, and obesity treatments, with potential deals and innovative drugs on the h

The next big thing in biotech? Your brain. From psychedelics for PTSD to precision Alzheimer's treatments and neural interface startups, neuroscience is drawing big attention, and even bigger investment.

Where cutting-edge tech meets human consciousness.

Explore the trends: https://headcount.ch/blog/life-science-industry-outlook-6-disruptive-trends-for-2025/

Life science industry outlook: 6 disruptive trends for 2025 | headcount 2025 is shaping up to be a rollercoaster of innovation, AI-driven madness, and mind-blowing discoveries that make sci-fi movies look outdated

The IPO market may be chilling, but biotech is still thriving—just in different ways.

With regulatory uncertainty and investor hesitation, M&A deals have become the lifeblood of biotech growth and exits in 2025. Why go public when you can get acquired?

Axios breaks it down: https://www.axios.com/newsletters/axios-pro-rata-74c27ee0-60c6-11f0-a510-f94a5236d169?

Axios Pro Rata Driving the news: Carlsmed, a personalized spine surgery company backed by B Capital Group and U.S. Venture Partners warned in its prospectus that "the current U.S. presidential administration" has issued policies to cut headcount and budgets in agencies including the FDA.

CRISPR, the revolutionary gene-editing tool, was first discovered in Streptococcus thermophilus—a bacterium used to make yogurt and cheese.

From dairy to DNA, biotech breakthroughs can come from the most unexpected places!

Looking to work in a field where curiosity pays off? Let BioPhase help you get there.

We’ve all heard that AI will revolutionize medicine, but where are the results?

While no AI-designed drugs have reached the market yet, companies like Recursion and Insilico are inching closer with multiple candidates now in clinical trials.
Could 2025 finally be the year AI makes its mark in biotech?

Explore the debate on WIRED: https://www.wired.com/story/artificial-intelligence-drug-discovery/

Where Are All the AI Drugs? In an industry where 90 percent of drug candidates fail before reaching the market, a handful of startups are betting everything on AI to beat the odds.

China’s New Obesity Drug Is Turning Heads

Chinese biotech firm Hengrui just dropped clinical trial results showing up to 19% average weight loss with their new drug HRS9531. This could signal a major shake-up in the global weight-loss drug race, and a wake-up call for North American pharma.

Want to see what real competition looks like? Read more on Barron's:

A Chinese Biotech’s Weight-Loss Drug Rivals Lilly’s Zepbound in Late-Stage Trial A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring to U.S. biopharma.

that the global biotech industry has surpassed $1 trillion in market size—and it’s still growing. With advances in AI, mRNA, and synthetic biology, the opportunities are endless.

If you're looking to grow your biotech career or team, BioPhase is your go-to partner.